Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.

Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany.
The Journal of Immunology (Impact Factor: 5.52). 06/2011; 187(2):1047-56. DOI: 10.4049/jimmunol.1002460
Source: PubMed

ABSTRACT The aim of this study was to investigate whether the specific T cell response against the multiple myeloma Ag HM1.24 is enhanced by the immunomodulatory drug lenalidomide (Revlimid). Ag-specific CD3(+)CD8(+) T cells against the HM1.24 Ag were expanded in vitro by dendritic cells in 29 healthy donors and 26 patients with plasma cell dyscrasias. Ag-specific activation was analyzed by IFN-γ, granzyme B, and perforin secretion using ELISA, ELISPOT assay, and intracellular staining, and generation of Ag-specific T cells was analyzed by tetramer staining. Expression of T cell maturation markers (CD45RA, CD45R0, CCR7, and CD28) was investigated by flow cytometry. We found that activation of HM1.24-specific T cells from healthy donors and patients with plasma cell dyscrasias was enhanced significantly by lenalidomide and furthermore that the impact of lenalidomide on T cells depends on the duration of the exposure. Notably, lenalidomide supports the downregulation of CD45RA on T cells upon activation, observed in healthy donors and in patients in vitro and also in patients during lenalidomide therapy in vivo. We showed for the first time, to our knowledge, that lenalidomide enhances the Ag-specific activation of T cells and the subsequent downregulation of CD45RA expression of T cells in vitro and in vivo.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently, it has been demonstrated that disease progression during HIV infection is not determined merely by the number of HIV-specific T cells but also by their quality (J. R. Almeida, et al., J. Exp. Med. 204:2473-2485, 2007; C. T. Berger, et al., J. Virol. 85:9334-9345, 2011; M. R. Betts, et al., Blood 107:4781-4789, 2006; V. V. Ganusov, et al., J. Virol. 85:10518-10528, 2011; P. Kiepiela, et al., Nat. Med. 13:46-53, 2007; and F. Pereyra, et al., J. Infect. Dis. 197:563-571, 2008). Therefore, strategies to specifically enhance or induce high-quality, HIV-specific T-cell responses are necessary to develop effective immune therapies. Thalidomide, lenalidomide, and pomalidomide have a strong capacity to boost immune responses and are therefore referred to as immunomodulatory drugs (IMiDs). We evaluated the effects of lenalidomide and pomalidomide on HIV-specific T cells. We found that the presence of IMiDs during in vitro T-cell stimulation with dendritic cells electroporated with Gag- or Nef-encoding mRNA resulted in higher numbers of cytokine-secreting HIV-specific CD8(+) T cells, particularly inducing polyfunctional HIV-specific CD8(+) T cells with an enhanced lytic capacity. Furthermore, CD8(+) T-cell responses were detected upon stimulation with lower antigenic peptide concentrations, and a higher number of Gag epitopes was recognized upon addition of IMiDs. Finally, IMiDs reduced the proliferation of the HIV-specific CD4(+) T cells while increasing the number of polyfunctional CD4(+) T cells. These results provide new information about the effects of IMiDs on antigen-specific T cells and suggest that these drugs increase the efficacy of immune therapies for infectious diseases and cancer.
    Journal of Virology 06/2012; 86(17):9351-60. · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: While IFN-α was the maintenance treatment of choice after autologous stem cell transplantation in multiple myeloma in the past, nowadays Thalidomide is commonly used. In this prospective study the implications of the various types of maintenance therapy on the patients T-cell pattern and activation status were assessed. T-cells were analyzed for expression of surface molecules, cytokine secretion, the presence of regulatory T-cells and the specific activation against the multiple myeloma antigen HM1.24. T-cells from 69 multiple myeloma patients were analyzed: 19 patients were treated with IFN-α, 26 with Thalidomide and 24 patients received no maintenance therapy. Specific T-cell activation with an immunogenic HLA-A2(+) restricted peptide from the myeloma associated antigen HM1.24 was impaired in the Thalidomide group. In accordance with this observation, there was a trend towards a higher amount of regulatory T-cells in the Thalidomide group. Furthermore, patients treated with IFN-α showed high rates of naïve T-cells, while in the Thalidomide group a high rate of effector memory T-cells was observed. Importantly, after cessation of Thalidomide, this effect was reversible in the CD8 compartment. In conclusion, Thalidomide maintenance therapy has profound implications on T-cell pattern and activation status which compromise antigen specific antitumor immunity.
    Experimental hematology 11/2012; · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to reverse tumor-mediated immune suppression and amplify myeloma-specific immunity is currently being explored. In the present study, we examined the effect of lenalidomide on T-cell activation and its ability to amplify responses to a dendritic cell-based myeloma vaccine. We demonstrate that exposure to lenalidomide in the context of T-cell expansion with direct ligation of CD3/CD28 complex results in polarization toward a Th1 phenotype characterized by increased IFN-γ, but not IL-10 expression. In vitro exposure to lenalidomide resulted in decreased levels of regulatory T cells and a decrease in T-cell expression of the inhibitory marker, PD-1. Lenalidomide also enhanced T-cell proliferative responses to allogeneic DCs. Most significantly, lenalidomide treatment potentiated responses to the dendritic cell/myeloma fusion vaccine, which were characterized by increased production of inflammatory cytokines and increased cytotoxic lymphocyte-mediated lysis of autologous myeloma targets. These findings indicate that lenalidomide enhances the immunologic milieu in patients with myeloma by promoting T-cell proliferation and suppressing inhibitory factors, and thereby augmenting responses to a myeloma-specific tumor vaccine.
    Cancer Immunology and Immunotherapy 06/2012; · 3.64 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014